A drug used for the treatment of prostate cancer is going off-patent in 2027. Another one, which ministers to Type 2 Diabetes is going off-patent in the same year too. And there are so many more of them, all going off-patent in 2027!
To make your work easy, we collected not just the names of the drug patents expiring in 2027, but also included other information like the yearly sales, treatment, ingredients, and the disease they cure which could help you easily choose the drug most profitable to develop a generic version.
So, without any delay, here is the list of drugs. Thank us later!
The article has a list of drug patents expiring in 2027. You can get the drug patents expiration list from 2026 to 2030 in a PDF by filling out the form below.
Procysbi
Cysteamine
| Patents | Expiration Date |
|---|---|
| US9925158 | January 26, 2027 |
| US9925157 | January 26, 2027 |
| US9925156 | January 26, 2027 |
Dosage: Oral, Eye drops
Company: Horizon Therapeutics plc
Ingredients: CYSTEAMINE BITARTRATE
Treatment: Cystinosis
Ongentys
Opicapone
| Patents | Expiration Date |
|---|---|
| US8907099 | May 12, 2027 |
| US8168793 | April 2, 2029 |
| US9630955 | December 12, 2032 |
Dosage: Oral
Company: Neurocrine Biosciences, Inc
Ingredients: OPICAPONE
Treatment: Parkinson’s Disease
Iclusig
Ponatinib
| Patents | Expiration Date |
|---|---|
| US8114874 | January 24, 2027 |
| US9493470 | December 12, 2033 |
| US11192897 | December 12, 2033 |
Dosage: Oral
Company: Takeda Pharmaceuticals
Ingredients: PONATINIB HYDROCHLORIDE
Treatment: Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive (Ph+), Acute Lymphoblastic Leukemia (ALL).
Ovide
Malathion
| Patents | Expiration Date |
|---|---|
| US7560445 | February 1, 2027 |
Dosage: Topical
Company: Taro Pharmaceuticals
Ingredients: MALATHION
Treatment: Pediculosis
Altabax
Retapamulin
| Patents | Expiration Date |
|---|---|
| US7875630 | February 14, 2027 |
Dosage: Topical
Company: GlaxoSmithKline
Ingredients: RETAPAMULIN
Treatment: Impetigo
Stribild
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil
| Patents | Expiration Date |
|---|---|
| US7176220 | February 27, 2027 |
| US7635704 | April 26, 2027 |
| US8981103 | April 26, 2027 |
Dosage: Oral
Company: Gilead Sciences Inc
Ingredients: COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Treatment: HIV/AIDS
Altabax
Retapamulin
| Patents | Expiration Date |
|---|---|
| US7176220 | February 27, 2027 |
| US7635704 | April 26, 2027 |
| US8981103 | April 26, 2027 |
Dosage: Oral
Company: Wyeth Pharmaceuticals Llc
Ingredients: BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED
Treatment: Hot Flashes, Osteoporosis
Stribild
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil
| Patents | Expiration Date |
|---|---|
| US7176220 | February 27, 2027 |
| US7635704 | April 26, 2027 |
| US8981103 | April 26, 2027 |
Dosage: Oral
Company: Gilead Sciences Inc
Ingredients: COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Treatment: HIV/AIDS
Duavee
Conjugated Estrogens/Bazedoxifene
| Patents | Expiration Date |
|---|---|
| US7683051 | March 10, 2027 |
Dosage: Oral
Company: Wyeth Pharmaceuticals Llc
Ingredients: BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED
Treatment: Hot Flashes, Osteoporosis
Zolinza
Vorinostat
| Patents | Expiration Date |
|---|---|
| US7456219 | March 11, 2027 |
Dosage: Oral
Company: Merck & Co
Ingredients: VORINOSTAT
Treatment: Cutaneous T Cell Lymphoma (CTCL)
Erleada
Apalutamide
| Patents | Expiration Date |
|---|---|
| US9388159 | March 27, 2027 |
| US8445507 | September 15, 2030 |
| US9481663 | June 4, 2033 |
Dosage: Oral
Company: Janssen-Cilag International NV
Ingredients: APALUTAMIDE
Treatment: Prostate Cancer
Varubi
Rolapitant
| Patents | Expiration Date |
|---|---|
| US8178550 | April 4, 2027 |
| US7049320 | August 19, 2028 |
Dosage: Oral
Company: Tesaro
Ingredients: ROLAPITANT HYDROCHLORIDE
Treatment: Chemotherapy-induced Nausea And Vomiting (CINV)
Symdeko
Tezacaftor-ivacaftor
| Patents | Expiration Date |
|---|---|
| US10239867 | April 9, 2027 |
| US8623905 | May 1, 2027 |
| US7645789 | May 1, 2027 |
| US7776905 | June 3, 2027 |
Dosage: Oral
Company: Vertex Pharmaceuticals Inc
Ingredients: IVACAFTOR; IVACAFTOR, TEZACAFTOR
Treatment: Cystic Fibrosis
Synjardy
Empagliflozin/Metformin
| Patents | Expiration Date |
|---|---|
| US7713938 | April 15, 2027 |
| US7579449 | August 1, 2028 |
Dosage: Oral
Company: Boehringer Ingelheim/Eli Lilly And Company
Ingredients: EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Treatment: Type 2 Diabetes
Savaysa
Edoxaban
| Patents | Expiration Date |
|---|---|
| US7365205 | April 18, 2027 |
Dosage: Oral
Company: Daiichi Sankyo
Ingredients: EDOXABAN TOSYLATE
Treatment: Venous Thromboembolism
Amyvid
Florbetapir (18f)
| Patents | Expiration Date |
|---|---|
| US8506929 | April 30, 2027 |
| US7687052 | April 30, 2027 |
Dosage: Intravenous Injection
Company: Avid Radiopharmaceuticals
Ingredients: FLORBETAPIR F-18
Treatment: Alzheimer’s
Mekinist
Trametinib
| Patents | Expiration Date |
|---|---|
| US7378423 | May 29, 2027 |
Dosage: Oral
Company: Novartis
Ingredients: TRAMETINIB DIMETHYL SULFOXIDE
Treatment: Melanoma
Altavera/Alysena/Amethyst
Ethinylestradiol/Levonorgestrel
| Patents | Expiration Date |
|---|---|
| US7838042 | June 1, 2027 |
Dosage: Oral
Company: Bayer Healthcare Pharmaceuticals
Ingredients: ETHINYL ESTRADIOL; LEVONORGESTREL
Treatment: Contraception
Xadago
Safinamide
| Patents | Expiration Date |
|---|---|
| US8278485 | June 8, 2027 |
| US8076515 | December 10, 2028 |
Dosage: Oral
Company: Newron Pharmaceuticals
Ingredients: SAFINAMIDE MESYLATE
Treatment: Parkinson’s Disease
Xadago
Safinamide
| Patents | Expiration Date |
|---|---|
| US8278485 | June 8, 2027 |
| US8076515 | December 10, 2028 |
Dosage: Oral
Company: Newron Pharmaceuticals
Ingredients: SAFINAMIDE MESYLATE
Treatment: Parkinson’s Disease
Antizol
Fomepizole
| Patents | Expiration Date |
|---|---|
| US7553863 | June 30, 2027 |
Dosage: Intravenous
Company: Paladin Labs
Ingredients: FOMEPIZOLE
Treatment: Ethylene Glycol And Methanol Poisoning
Vokanamet
Canagliflozin/Metformin
| Patents | Expiration Date |
|---|---|
| US7943788 | July 14, 2027 |
| US8513202 | December 3, 2027 |
| US7943582 | February 26, 2029 |
Dosage: Intravenous
Company: Janssen-cilag International Nv
Ingredients: CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Treatment: Type 2 Diabetes
Asacol/Lialda/Pentasa
Mesalazine
| Patents | Expiration Date |
|---|---|
| US7645801 | July 24, 2027 |
Dosage: Oral, Rectal
Company: Tillotts Pharma Ag.
Ingredients: MESALAMINE
Treatment: Ulcerative Colitis And Crohn’s Disease
Daklinza
Daclatasvir
| Patents | Expiration Date |
|---|---|
| US9421192 | August 8, 2027 |
| US8642025 | August 11, 2027 |
| US8329159 | July 24, 2029 |
| US8629171 | June 13, 2031 |
Dosage: Oral
Company: Bristol-Myers Squibb
Ingredients: DACLATASVIR DIHYDROCHLORIDE
Treatment: Hepatitis C
Xtandi
Enzalutamide
| Patents | Expiration Date |
|---|---|
| US7709517 | August 13, 2027 |
Dosage: Oral
Company: Astellas Pharma Inc.
Ingredients: ENZALUTAMIDE
Treatment: Prostate Cancer
Azilect
Rasagiline
| Patents | Expiration Date |
|---|---|
| US7815942 | August 27, 2027 |
Dosage: Oral
Company: Teva Pharmaceutical
Ingredients: RASAGILINE MESYLATE
Treatment: Parkinson’s Disease
Tivicay
Dolutegravir
| Patents | Expiration Date |
|---|---|
| US8129385 | October 5, 2027 |
| US9242986 | December 8, 2029 |
| US10426780 | January 24, 2031 |
Dosage: Oral
Company: Viiv Healthcare
Ingredients: DOLUTEGRAVIR SODIUM
Treatment: HIV/AIDS
Imcivree
Setmelanotide
| Patents | Expiration Date |
|---|---|
| US9458195 | October 13, 2027 |
| US8039435 | October 13, 2027 |
Dosage: Subcutaneous
Company: Rhythm Pharmaceutical
Ingredients: SETMELANOTIDE ACETATE
Treatment: Genetic Obesity
Xcopri
Cenobamate
| Patents | Expiration Date |
|---|---|
| US7598279 | October 30, 2027 |
Dosage: Subcutaneous
Company: SK Biopharmaceuticals
Ingredients: CENOBAMATE
Treatment: Partial Epilepsies
Pylarify
Piflufolastat F-18
| Patents | Expiration Date |
|---|---|
| US10793596 | November 12, 2027 |
| US10017536 | November 12, 2027 |
| US8536131 | November 12, 2027 |
| US7727963 | November 12, 2027 |
| US7713937 | November 12, 2027 |
| US7402564 | November 12, 2027 |
Dosage: Intravenous
Company: Progenics Pharmaceuticals
Ingredients: PIFLUFOLASTAT F-18
Treatment: Prostate Cancer Metastasis
Korsuva
Difelikefalin
| Patents | Expiration Date |
|---|---|
| US8487129 | November 7, 2027 |
| US9861713 | July 31, 2029 |
| US8778305 | September 21, 2030 |
| US10947197 | June 9, 2037 |
Dosage: Intravenous
Company: Cara Therapeutics
Ingredients: DIFELIKEFALIN ACETATE
Treatment: Itching
Empaveli
Pegcetacoplan
| Patents | Expiration Date |
|---|---|
| US9169307 | November 18, 2027 |
| US7989589 | December 4, 2027 |
| US7888323 | December 4, 2027 |
| US10125171 | August 2, 2033 |
| US10875893 | November 15, 2033 |
| US10035822 | November 15, 2033 |
Dosage: Subcutaneous
Company: Apellis Pharmaceuticals/Swedish Orphan Biovitrum
Ingredients: PEGCETACOPLAN
Treatment: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Tabrecta
Capmatinib
| Patents | Expiration Date |
|---|---|
| US8461330 | November 19, 2027 |
| US7767675 | November 19, 2027 |
| US8420645 | June 5, 2031 |
| US10596178 | July 22, 2035 |
Dosage: Subcutaneous
Company: Novartis Pharmaceuticals
Ingredients: CAPMATINIB HYDROCHLORIDE
Treatment: Non-small Cell Lung Cancer (NSCLC)
Turalio
Pexidartinib
| Patents | Expiration Date |
|---|---|
| US9169250 | November 21, 2027 |
| US8404700 | November 21, 2027 |
| US8722702 | November 21, 2027 |
| US7893075 | October 13, 2028 |
| US10730876 | May 5, 2036 |
| US9802932 | May 5, 2036 |
Dosage: Subcutaneous
Company: Daiichi Sankyo Company
Ingredients: PEXIDARTINIB HYDROCHLORIDE
Treatment: Tenosynovial Giant Cell Tumor (TGCT)
Toradol/Biorolac
Ketorolac
| Patents | Expiration Date |
|---|---|
| US8008338 | November 24, 2027 |
| US7842714 | August 15, 2029 |
Dosage: Oral, Intramuscular, Intravenous, Eye drops, Nasal spray
Company: Cadila Healthcare Limited
Ingredients: KETOROLAC TROMETHAMINE
Treatment: Pain
Entresto
Sacubitril/Valsartan
| Patents | Expiration Date |
|---|---|
| US8877938 | November 27, 2027 |
Dosage: Oral
Company: Novartis
Ingredients: SACUBITRIL; VALSARTAN
Treatment: Heart Failure
Xermelo
Telotristat Ethyl
| Patents | Expiration Date |
|---|---|
| US7709493 | December 11, 2027 |
| US7553840 | December 11, 2027 |
| US8193204 | February 27, 2031 |
Dosage: Oral
Company: Lexicon Pharmaceuticals
Ingredients: TELOTRISTAT ETIPRATE
Treatment: Carcinoid Syndrome Diarrhea
Jakafi
Ruxolitinib
| Patents | Expiration Date |
|---|---|
| US8415362 | December 24, 2027 |
| US7598257 | December 24, 2027 |
| US8722693 | June 12, 2028 |
Dosage: Oral, Topical
Company: Incyte Corp/Novartis
Ingredients: RUXOLITINIB PHOSPHATE
Treatment: Myelofibrosis
Nexavar
Sorafenib
| Patents | Expiration Date |
|---|---|
| US8877933 | December 24, 2027 |
Dosage: Oral, Topical
Company: Bayer/Onyx Pharmaceuticals
Ingredients: SORAFENIB TOSYLATE
Treatment: Renal Cell Carcinoma
